Ownership and insider activity for Gain Therapeutics, Inc. (GANX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins.
Price
| Price | $1.72 |
| Market Cap | $73M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-15 | GOLDSTEIN DOV A MD | A-Award | 25,000 | $42K |
| 2026-07-15 | Nicaise Claude | A-Award | 25,000 | $42K |
| 2026-07-15 | Islam Khalid | A-Award | 25,000 | $42K |
| 2026-07-15 | Melincoff Gwen A | A-Award | 25,000 | $42K |
| 2026-07-15 | Riley Jeffrey Scott | A-Award | 25,000 | $42K |
| 2026-07-15 | HASLER HANS PETER | A-Award | 25,000 | $42K |
| 2026-03-24 | Mack Gene | A-Award | 200,000 | $372K |
| 2026-03-24 | Fuggetta Gianluca | A-Award | 50,000 | $93K |
| 2025-06-24 | Islam Khalid | A-Award | 15,000 | $27K |
| 2025-06-24 | Nicaise Claude | A-Award | 15,000 | $27K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $400694 | $303320 | $7.5M | $36.9M | $7.3M | $11.8M | $10.4M | $20.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | $12.8M | $5.0M | 0 | 0 |
| Receivables | 0 | $44915 | $8548 | $195448 | $103877 | $242577 | $765763 | $802693 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $494638 | $398047 | $9.0M | $37.7M | $21.1M | $17.8M | $11.6M | $22.2M |
| Property, Plant & Equipment | $305787 | $219348 | $552713 | $1.0M | $804312 | $585177 | $323334 | $409006 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | $202609 | $213967 | $193375 | $134268 | $102837 |
| Total Assets | $811634 | $660286 | $9.6M | $39.0M | $24.1M | $18.6M | $12.1M | $22.8M |
| Accounts Payable | $149333 | $154441 | $961516 | $560479 | $1.6M | $1.3M | $946259 | $825027 |
| Short-term Debt | 0 | $102107 | $22626 | $103826 | $108135 | $118797 | $110177 | $100869 |
| Total Current Liabilities | $530786 | $879052 | $2.1M | $2.6M | $4.1M | $4.9M | $3.9M | $3.4M |
| Long-term Debt | $1.0M | 0 | $715656 | $590468 | $495258 | $449053 | $328327 | $300084 |
| Total Liabilities | $1.8M | $1.1M | $3.4M | $4.2M | $5.2M | $6.0M | $4.8M | $4.3M |
| Retained Earnings | -$1.3M | -$3.5M | -$7.0M | -$20.9M | -$38.5M | -$60.8M | -$81.2M | -$101.4M |
| Total Equity | -$950908 | -$449856 | $6.2M | $34.8M | $18.9M | $12.6M | $7.3M | $18.6M |
| Total Debt | $1.3M | $200950 | $1.3M | $1.6M | $1.3M | $1.0M | $653015 | $732067 |
| Net Debt | $904670 | -$102370 | -$6.2M | -$35.3M | -$18.9M | -$15.8M | -$9.7M | -$20.1M |
| Working Capital | -$36148 | -$481005 | $6.9M | $35.2M | $17.0M | $12.8M | $7.7M | $18.9M |
Financial Health
| Debt / Equity | 0.05 |
| Current Ratio | 4.36 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 7.04 |
Profitability
| Return on Equity | -161.58% |
| Return on Invested Capital | -157.82% |
| Return on Assets | -130.37% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACET · ADAG · CRVO · FBIO · LITS · NRXP · NTRB
Explore sector: Healthcare · Biotechnology
More sections of GANX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks